Braskem's $11B debt talks are collapsing days before the deadline — short the stock into October 9
With creditors rejecting the proposal and a binding October 9 deadline, the odds of a disorderly default or heavily dilutive restructuring have jumped, and that risk isn't fully priced into the equity. Failed negotiations on a hard deadline tend to trigger sharp repricing as investors scramble for the exits. The event gives a clear date, making this a defined-risk short rather than an open-ended bet.
Idea
With creditors rejecting the proposal and a binding October 9 deadline, the odds of a disorderly default or heavily dilutive restructuring have jumped, and that risk isn't fully priced into the equity. Failed negotiations on a hard deadline tend to trigger sharp repricing as investors scramble for the exits. The event gives a clear date, making this a defined-risk short rather than an open-ended bet.
Advanced Analysis — institutional-depth research report
Verdict: let the October 9 deadline resolve before touching this short
This is a dated, binary event thesis: creditors have rejected Braskem's restructuring proposal with a binding October 9 deadline looming (per the Bloomberg piece published October 7, 2026), and the idea argues a failed resolution should trigger sharp repricing of an equity already carrying a BRL 11.3B net loss, negative BRL 4.8B equity, and negative BRL 1.3B free cash flow in FY2024. The strongest point for the trade is that hard-date creditor failures remove the usual ambiguity of distressed situations — either terms are agreed or the equity faces a disorderly or heavily dilutive outcome. The strongest point against is that the cash engine is stabilizing — operating cash flow swung from negative BRL 2.3B in 2023 to positive BRL 2.4B in 2024 and gross margin rose to 7.7% from 4.3% — which makes a last-minute settlement, and a relief rally against shorts, genuinely likely. On the rules side, this is a watch-list setup, not an active signal: no entries fired across the 186 daily bars evaluated in the most recent nine-month window, which is intrinsic to a mandate that forbids pre-positioning ahead of the deadline. The stock closed at $1.77, already $0.06 below the $1.83 support rank, with ADX (14) at 20.34 just above its 20 entry threshold, so the breakdown trigger is close but not armed. A confirmed creditor agreement before October 9 — or a daily close reclaiming and holding above $1.83 — would flip this verdict.
Trade now: waiting on the October 9 deadline, not pre-positioning
BAK closed at $1.77 with RSI (14) at 65.1, and this is a watch-list setup, not an active signal: the strategy's entry conditions have not fired over the last 186 daily bars, which is the expected behavior of a date-specific event thesis rather than a trust deficit. The mandate forbids pre-positioning ahead of the binding October 9 creditor deadline that the idea centers on. Entry requires three things together: the close sitting above the nearest support level (currently $1.83, so price is $0.06 below it — not met), ADX (14) above 20 (currently 20.34 — met), and then a confirmed daily close crossing below that support level. Two of three live conditions are not aligned, so today's action is to wait, concretely: no position until the deadline resolves and price breaks and holds below the pre-event range low. Once triggered, risk is defined mechanically: the stop is a 2.8% loss on the position (with a structural stop on a close back below the first support rank), and the first profit target is a 5.5% gain — an effective reward-to-risk of roughly 2:1. Position size is capped at 2.75% risk per trade and 25% of the book. The bearish case the idea argues is event-driven: per the idea, creditors rejected the restructuring proposal, raising the odds of a disorderly default or heavily dilutive outcome that the equity has not fully priced. The fundamentals reinforce why the equity is fragile — FY2024 net income was -11.3B BRL (net margin -14.6%, deteriorating from -6.5%), free cash flow was -1.3B BRL, and the stock's trailing twelve months have paid no dividend while the last recorded payment was $0.674 per share in April 2022. What waiting means in practice: hold no position through the October 9 deadline itself. If the deadline passes with a negotiated resolution and the stock gaps up, the breakdown trigger never arms and the idea is dead — do not chase. If the deadline produces the sharp repricing the thesis expects, the entry arms only after a confirmed daily close below the $1.83 support rank while ADX (14) holds above 20, so the wait has a hard end date. Note one factual scope limit that materially affects the plan: market-data coverage for the strategy's dependency series is incomplete, so longer historical windows could not be run and the evaluable window is the most recent 9 months.
A Hard Deadline With Rejected Terms Is the Cleanest Bear Catalyst There Is
The thesis rests on a dated, binary event, and the reporting backs the setup: per Bloomberg's October 7, 2026 piece, creditors have balked at Braskem's restructuring proposal with a binding October 9 deadline looming. A rejected proposal against a hard date removes the usual ambiguity of distressed situations — either terms get agreed, or the company faces a disorderly default or a heavily dilutive restructuring. Either branch is bad for the equity, and the idea's core claim that this…
Scores
- Conviction score breakdown: 55
- Thesis support: 65
- Trade readiness: 45
- Risk quality: 60
- Trigger proximity: 70
- Fundamentals trend: 35
Watch items
- BAK — Daily close vs nearest support level
- BAK — ADX (14)
- BAK — ADX (14) exit threshold
- BAK — Creditor deadline resolution
- BAK — Downside extension level
- BAK — Price reclaim of support